英国胃肠病学会成人肝细胞癌管理指南
英国胃肠病学会发布成人肝细胞癌管理指南,指出英国肝细胞癌发病率和死亡率上升,5年生存率低于20%,性别、种族和贫困是重要人口学因素。指南基于英国可用且获国民健康服务体系批准的疗法,提供循证评估和管理建议。
要点
- 肝细胞癌为高致死性癌症,常诊断较晚,发病死亡率比接近1。
- 英国肝细胞癌5年生存率仍低于20%。
- 指南治疗算法基于英国可用且获国民健康服务体系批准的疗法。
核心结论
- 指南为肝细胞癌患者的评估和管理提供循证建议,治疗算法基于英国可用且获国民健康服务体系批准的疗法。
研究设计与样本
- 英国胃肠病学会制定,基于临床和科学数据总结证据并给出建议。
主要发现
- 英国肝细胞癌发病率与死亡率上升,5年生存率低于20%。
- 肝细胞癌发病死亡率比接近1。
- 性别、种族和贫困是肝细胞癌发病和/或生存的重要人口学因素。
关键数值与推荐
- 治疗算法基于英国可用且获国民健康服务体系批准的疗法。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Deaths from the majority of cancers are falling globally, but the incidence and mortality from hepatocellular carcinoma (HCC) is increasing in the United Kingdom and in other Western countries. HCC is a highly fatal cancer, often diagnosed late, with an incidence to mortality ratio that approaches 1. Despite there being a number of treatment options, including those associated with good medium to long-term survival, 5-year survival from HCC in the UK remains below 20%. Sex, ethnicity and deprivation are important demographics for the incidence of, and/or survival from, HCC. These clinical practice guidelines will provide evidence-based advice for the assessment and management of patients with HCC. The clinical and scientific data underpinning the recommendations we make are summarised in detail. Much of the content will have broad relevance, but the treatment algorithms are based on therapies that are available in the UK and have regulatory approval for use in the National Health Service.
引用
- Suddle A, Reeves H, Hubner R, et al. British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults. Gut. 2024. PMID: 38627031. doi:10.1136/gutjnl-2023-331695
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。